Acrivon Therapeutics, Inc.
corporate_fare Company Profile
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ACRV at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 9 rated 8 or above. Recent SEC coverage for ACRV spans 8-K, S-3, 10-Q, DEFA14A.
Recent high-impact activity:
- Acrivon Presents ACR-2316 Phase 1/2 Data: Confirmed CR in Lung Cancer, No DLTs at Selected Doses
- Acrivon Files New $300M Shelf Days After Disclosing Going-Concern Doubt
- Acrivon Q3 Loss Narrows to $17.9M; $77.8M Cash Funds Operations Into Q4 2027
- Acrivon Q3 2026: $77.8M Cash, but Substantial Going-Concern Doubt
- Acrivon Details ACR-525 JAK1 Data and EoE Phase 2 Plan at R&D Event
Financial Snapshot
Short Interest & Short Volume
11.37 days to coverFINRA reported short interest of 1,804,674 shares in ACRV as of the October 30, 2026 settlement, a 3.9% increase from the prior period — about 11.4 days to cover at its recent average daily volume. On November 20, 2026, 45.7% of ACRV volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ACRV, detected from its recent SEC filings.
New $300M Universal Shelf Filed · Most Capacity Is Rolled Forward
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →